China Biotech Services Holdings (HKSE:08037) LT-Debt-to-Total-Asset : 0.01 (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. China Biotech Services Holdings's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.01.

China Biotech Services Holdings's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Jun. 2024 (0.01). It may suggest that China Biotech Services Holdings is progressively becoming more dependent on debt to grow their business.

China Biotech Services Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for China Biotech Services Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biotech Services Holdings LT-Debt-to-Total-Asset Chart

China Biotech Services Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.09

0.01

0.04

0.01

China Biotech Services Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.07	-	0.01	0.01

China Biotech Services Holdings LT-Debt-to-Total-Asset Calculation

China Biotech Services Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	5.727	/	662.362
	=	0.01

China Biotech Services Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	3.967	/	630.553
	=

China Biotech Services Holdings (HKSE:08037) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

China Biotech Services Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biotech Services Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG

Website

http://www.cbshhk.com

China Biotech Services Holdings Ltd is an investment holding company. It operates through six segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Securities, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.

Executives

Liu Xiaolin	2101 Beneficial owner
Genius Earn Limited	2201 Interest of corporation controlled by you
Genius Lead Limited	2101 Beneficial owner
Guoyuan International Holdings Limited	2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd.	2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited	2101 Beneficial owner
Richlane Ventures Limited	2101 Beneficial owner
Ko Chun Shun, Johnson	2201 Interest of corporation controlled by you

China Biotech Services Holdings Headlines

No Headlines